Results 121 to 130 of about 116,651 (165)
Serotonergic Modulators in Alzheimer's Disease: A Hope in the Hopeless Condition
ABSTRACT Alzheimer's disease (AD) is the main cause of dementia worldwide. AD is a progressive brain neurodegenerative disease due to genetic and environmental factors that induce a progressive accumulation of intracellular hyperphosphorylated tau protein and extracellular amyloid protein (Aβ).
Najlaa Hamed Almohmadi+7 more
wiley +1 more source
ABSTRACT The subfamily Gomphrenoideae is composed of about 480 accepted species, many of which have been historically used as medicinal plants, reason why they have been studied in terms of chemical profile, biological activity, and safety. This review consolidates the advances in research on this subfamily over the past 47 years, emphasizing its ...
Dayanna Isabel Araque Gelves+3 more
wiley +1 more source
Bioactives From Brown Algae: Antioxidant, Anti‐Inflammatory, Anticancer, and Antimicrobial Potential
This review explores key bioactives in brown algae and their antioxidant, anti‐inflammatory, anticancer, and antimicrobial properties. Covering studies from 2014 to 2024, it highlights their relevance in pharmaceuticals, nutraceuticals, cosmetics, and foods, while addressing challenges and future directions to unlock their full potential.
Irvin Fonseca‐Barahona+2 more
wiley +1 more source
PCFT‐Independent Cellular Uptake of Cyclic Cell‐Penetrating Peptide‐Conjugated Folic Acid
Cell‐penetrating peptide (CPP)‐conjugated folic acid mediates efficient internalization of folic acid that is independent of the presence of proton‐coupled folate transporter (PCFT) on the intestinal cells. CPP‐conjugated folic acid demonstrates superior cellular uptake at all studied pH and in the presence of PCFT inhibitors and shows enhanced ...
Vineet Kumar Mishra+3 more
wiley +1 more source
Donanemab, approved by the U.S. FDA in July 2024, targets amyloid plaques in the brain to treat Alzheimer's disease in patients with mild cognitive impairment or mild dementia. ABSTRACT Substantial research has been conducted to identify an efficient treatment for Alzheimer's disease (AD).
Nandhini Jayaprakash+1 more
wiley +1 more source
Amyloid‐Related Imaging Abnormality (ARIA) Beyond the APOE‐ε4 Allele
Mechanism of action of monoclonal antibodies targeting Aβ in the treatment of AD. (A) Targets of various mAbs. (B) Mechanism of monoclonal antibody‐mediated clearance of Aβ. mAbs facilitate the clearance of Aβ by enhancing microglial‐mediated phagocytosis through the upregulation of TREM2 expression.
Valentinus Besin+5 more
wiley +1 more source
A chemical probe CBN‐P based on the neuroprotective cannabinoid cannabinol (CBN) was developed and synthesized. CNB‐P was found to have a similar mechanism of action as the parent compound and was used in click‐CLEM microscopy studies and affinity‐based protein profiling to identify the mitochondrial protein isocitrate dehydrogenase 2 (IDH2) as one ...
Eva Schaller+5 more
wiley +1 more source
TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques [PDF]
Cella, Marina+11 more
core +2 more sources
The cannabinoid receptor type 2 (CB2R) is overexpressed under pathological conditions. PET is a suitable non‐invasive imaging technique for diagnosing disease states, but requires a radiotracer that binds to CB2R with high affinity and selectivity. Currently, there is no suitable candidate routinely used in the clinics.
Lea Ueberham+4 more
wiley +1 more source
Abstract Background The endocannabinoid system is a neuromodulatory system implicated in cellular processes during both development and regeneration. The Mexican axolotl, one of only a few vertebrates capable of central nervous system regeneration, was used to examine the role of the endocannabinoid system in the regeneration of the tail and spinal ...
Michael Tolentino+3 more
wiley +1 more source